DME competitive bidding momentum
This article was originally published in The Gray Sheet
One-year freeze on durable medical equipment spending, followed by competitive bidding implementation, likely will be included in the final Medicare reform package, according to device stakeholders. The new technology provisions also are coming under scrutiny, as conferees look to keep the "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1, S 1) under the $400 bil. figure proposed by President Bush. Working with lawmakers, AdvaMed has succeeded in reducing the new tech score to $1.5 bil., but conferees may try to lower the amount to $1 bil. or less...
You may also be interested in...
CMS Administrator Tom Scully is no longer confident that the Medicare reform conference committee will be able to agree on a final product, let alone produce a bill that can pass both chambers
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.